EP2432761 - TREATMENT OF MUSCLE DISEASE CHARACTERIZED BY INSULIN RESISTANCE [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 08.12.2017 Database last updated on 09.09.2024 | |
Former | Grant of patent is intended Status updated on 24.02.2017 | Most recent event Tooltip | 08.12.2017 | Application deemed to be withdrawn | published on 10.01.2018 [2018/02] | Applicant(s) | For all designated states Ottawa Hospital Research Institute 725 Parkdale Avenue Ottawa, ON K1Y 4E9 / CA | For all designated states Fate Therapeutics (Canada) Inc. c/o 3535 General Atomics Court Suite 200 San Diego, California 92121 / US | [N/P] |
Former [2012/13] | For all designated states Ottawa Hospital Research Institute 725 Parkdale Avenue Ottawa, ON K1Y 4E9 / CA | ||
For all designated states Fate Therapeutics (Canada) Inc. C/o 3535 General Atomics Court Suite 200 San Diego, California 92121 / US | Inventor(s) | 01 /
MEGENEY, Lynn 1609 Alta Vista Drive Ottawa Ontario K1G 0G4 / CA | 02 /
EVANS, Carol 61 Clifford Private Ottawa Ontario KlG 4Y2 / CA | 03 /
SLASSI, Abdelmalik 4780 Fulwell Road Mississauga Ontario L5M 7J7 / CA | [N/P] |
Former [2012/13] | 01 /
MEGENEY, Lynn 1609 Alta Vista Drive Ottawa Ontario K1G 0G4 / CA | ||
02 /
EVANS, Carol 61 Clifford Private Ottawa Ontario KlG 4Y2 / CA | |||
03 /
SLASSI, Abdelmalik 4780 Fulwell Road Mississauga Ontario L5M 7J7 / CA | Representative(s) | Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE | [N/P] |
Former [2012/13] | Schiweck, Weinzierl & Koch European Patent Attorneys Landsberger Straße 98 80339 München / DE | Application number, filing date | 10777262.6 | 18.05.2010 | WO2010CA00734 | Priority number, date | US20090179040P | 18.05.2009 Original published format: US 179040 P | US20090244669P | 22.09.2009 Original published format: US 244669 P | [2012/13] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2010132982 | Date: | 25.11.2010 | Language: | EN | [2010/47] | Type: | A1 Application with search report | No.: | EP2432761 | Date: | 28.03.2012 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.11.2010 takes the place of the publication of the European patent application. | [2012/13] | Search report(s) | International search report - published on: | CA | 25.11.2010 | (Supplementary) European search report - dispatched on: | EP | 13.11.2012 | Classification | IPC: | A61K31/155, A61P21/00 | [2012/50] | CPC: |
C07C313/30 (EP,US);
A61K31/155 (EP,US);
A61P21/00 (EP);
C07F9/657154 (EP,US);
C07C2601/14 (EP,US);
G01N2333/62 (EP,US);
|
Former IPC [2012/13] | C07C279/26, A61K31/155, A61P21/00, C07C313/30, G01N33/74 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/13] | Title | German: | VERFAHREN ZUR BEHANDLUNG VON DURCH INSULINRESISTENZ GEKENNZEICHNETEN MUSKELERKRANKUNGEN | [2012/13] | English: | TREATMENT OF MUSCLE DISEASE CHARACTERIZED BY INSULIN RESISTANCE | [2012/13] | French: | TRAITEMENT D'UNE MALADIE MUSCULAIRE CARACTÉRISÉE PAR UNE RÉSISTANCE À L'INSULINE | [2012/13] | Entry into regional phase | 12.12.2011 | National basic fee paid | 12.12.2011 | Search fee paid | 12.12.2011 | Designation fee(s) paid | 12.12.2011 | Examination fee paid | Examination procedure | 12.12.2011 | Examination requested [2012/13] | 04.06.2013 | Amendment by applicant (claims and/or description) | 28.10.2013 | Despatch of a communication from the examining division (Time limit: M02) | 23.12.2013 | Reply to a communication from the examining division | 22.01.2014 | Despatch of a communication from the examining division (Time limit: M04) | 30.05.2014 | Reply to a communication from the examining division | 13.04.2015 | Despatch of a communication from the examining division (Time limit: M02) | 22.06.2015 | Reply to a communication from the examining division | 19.11.2015 | Despatch of a communication from the examining division (Time limit: M02) | 29.01.2016 | Reply to a communication from the examining division | 03.03.2017 | Communication of intention to grant the patent | 14.07.2017 | Application deemed to be withdrawn, date of legal effect [2018/02] | 23.08.2017 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2018/02] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 28.10.2013 | Fees paid | Renewal fee | 25.05.2012 | Renewal fee patent year 03 | 28.05.2013 | Renewal fee patent year 04 | 27.05.2014 | Renewal fee patent year 05 | 27.05.2015 | Renewal fee patent year 06 | 27.05.2016 | Renewal fee patent year 07 | Penalty fee | Additional fee for renewal fee | 31.05.2017 | 08   M06   Not yet paid |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [E]WO2011121109 (INST NAT SANTE RECH MED [FR], et al) [E] 1-8,12-14 * claims 1-12 *; | [AP]WO2009112439 (JANSSEN PHARMACEUTICA NV [BE], et al) [AP] 1-14 * table 3 * * claim 16 *; | [E]WO2010080581 (UNIV NEVADA [US], et al) [E] 1-8 * claim 23 * | [XI] - KASHIWAGI KEN-ICHIRO ET AL, "Troglitazone not only reduced insulin resistance but also improved myotonia in a patient with myotonic dystrophy", BIOSIS,, (19990401), XP002594594 [X] 1-4,7,8 * the whole document * [I] 5,6,9-11 | International search | [A]WO2007134867 (DSM IP ASSETS BV [NL], et al); | [X]GB607720 (ARTHUR DONALD AINLEY, et al); | [X]US3152181 (LOUIS FREEDMAN, et al); | [X]US3366650 (JACK BERNSTEIN, et al); | [X]US3147271 (SHAPIRO SEYMOUR L, et al); | [X]US3531484 (BICKING JOHN B, et al); | [X]US5434142 (ANTOKU YASUNOBU [JP], et al); | [XP] - HUTTUNEN, K.M. ET AL., J. MED. CHEM., (20090612), vol. 52, pages 4142 - 4148, XP008152149 DOI: http://dx.doi.org/10.1021/jm900274q | [X] - HUTTUNEN, K.M. ET AL., "Determination of metformin and its prodrugs in human and rat blood by hydrophilic interaction liquid chromatography", J. PHARMA. BIOMED. ANALYSIS, (20090507), vol. 50, pages 469 - 474, XP026321335 DOI: http://dx.doi.org/10.1016/j.jpba.2009.04.033 | [X] - HUTTUNEN, K.M. ET AL., SYNTHESIS, (2008), pages 3619 - 3624, XP008152150 DOI: http://dx.doi.org/10.1055/s-0028-1083603 | [AP] - ABE, H. ET AL., ENDOCRINE JOURNAL 2009, (20090609), vol. 56, pages 911 - 913, XP008152633 DOI: http://dx.doi.org/10.1507/endocrj.K09E-122 | [A] - KOUKI, T. ET AL., DIABETIC MEDICINE, (2005), vol. 22, pages 346 - 347, XP008152153 DOI: http://dx.doi.org/10.1111/j.1464-5491.2005.01432.x | [A] - PICCARDO, M.G. ET AL., ENZYME, (1991), vol. 45, pages 14 - 22, XP008154276 | [X] - ANGELINI, C. ET AL., MUSCLE NERVE, (2007), vol. 36, pages 424 - 435, XP008152182 DOI: http://dx.doi.org/10.1002/mus.20812 | [X] - AINLEY, A.D. ET AL., J. CHEM. SOC., (1949), pages 98 - 106, XP008154353 DOI: http://dx.doi.org/10.1039/jr9490000098 | [X] - SRINIVAS, K.S. ET AL., J. INDIAN. INST. SCI., (1953), vol. 35 A, pages 47 - 54, XP008152152 | [X] - RUNTI, C. ET AL., IL FARMACO, (1968), vol. 23, pages 827 - 841 | [X] - COLAUTTI, A. ET AL., IL FARMACO, (1971), vol. 26, pages 850 - 856, XP008152187 | [X] - LIU, Z. ET AL., "The antidiabetic effects of cysteinyl metformin, a newly synthesized agent, inalloxan- and streptozocin-induced diabetic rats", CHEMICO-BIOLOGICAL INTERACTIONS, (2008), vol. 173, pages 68 - 75, XP022612926 DOI: http://dx.doi.org/10.1016/j.cbi.2007.11.012 | [X] - SHAPIRO, S. L. ET AL., J. AM. CHEM. SOC., (1959), vol. 81, pages 4635 - 4639, XP008154896 DOI: http://dx.doi.org/10.1021/ja01526a047 | [X] - DUAN, Z-L. ET AL., "Synthesis and Study of Antidiabetic Properties of the Neodymium Complexe with N- [o-(un) Substituted Benzoyl]-N, N-Dimethylbiguanide", CHINESE J. CHEM., (2007), vol. 25, pages 1919 - 1923, XP008153160 DOI: http://dx.doi.org/10.1002/cjoc.200790353 | [X] - KHAN, M. A. ET AL., J. NERUOL. SCI., (1993), vol. 120, pages 8 - 14, XP024298817 DOI: http://dx.doi.org/10.1016/0022-510X(93)90017-S | by applicant | WO2011121109 | WO2010080581 | - HUTTUNEN ET AL., J. MED. CHEM., (2009), vol. 52, pages 4142 - 4148 | - HUTTUNEN ET AL., J. PHARMA. BIOMED. ANALYSIS, (2009), vol. 50, pages 469 - 474 | - HUTTUNEN ET AL., SYNTHESIS, (2008), pages 3619 - 3624 | - ABE ET AL., ENDOCRINE JOURNAL, (2009), vol. 56, pages 911 - 913 | - KOUKI ET AL., DIABETIC MEDICINE, (2005), vol. 22, pages 346 - 347 | - ANGELINI ET AL., MUSCLE NERVE, (2007), vol. 26, pages 424 - 435 | - KHAN ET AL., J NEUROL. SCI., (1993), vol. 120, pages 8 - 14 | - HOFFMAN ET AL., N. ENGL. J. MED., (1988), vol. 318, pages 1363 - 1368 | - BONNEMANN, C. G. ET AL., CURR. OPIN. PED., (1996), vol. 8, pages 569 - 582 | - WORTON, R., SCIENCE, (1995), vol. 270, pages 755 - 756 | - FUNAKOSHI, M. ET AL., NEUROMUSCUL. DISORD., (1999), vol. 9, no. 2, pages 108 - 114 | - LIM, L. E.; CAMPBELL, K. P., CURE. OPIN. NEUROL., (1998), vol. 11, no. 5, pages 443 - 452 | - VOIT, T., BRAIN DEV., (1998), vol. 20, no. 2, pages 65 - 74 | - BROWN, R. H., ANNU. REV. MED., (1997), vol. 48, pages 457 - 466 | - FISHER, J.; UPADHYAYA, M., NEUROMUSCUL. DISORD., (1997), vol. 7, no. 1, pages 55 - 62 | - E. L. ELIEL; S. H. WILEN, Stereochemistry of Carbon Compounds, JOHN WILEY & SONS, (1994), pages 1119 - 1190 | - MERRIFELD, AM. CHEM. SOC., (1963), vol. 85, page 2149 | - MERRIFELD, SCIENCE, (1986), vol. 232, page 341 | - BITTNER ET AL., METHODS IN ENZYMOL., (1987), vol. 153, page 516 | - ZAMORE, NATURE STRUC. BIOL., (2001), vol. 8, pages 746 - 750 | - Current Protocols in Protein Science, J. WILEY & SONS | - SHARP NJ ET AL., GENOMICS, (1992), vol. 13, no. 1, pages 115 - 121 | - WILLMANN R. ET AL., NEUROMUSCULAR DISORDERS, (2009), vol. 19, pages 241 - 249 | - VAINZOF M. ET AL., J MOL NEUROSCI., (2008), vol. 34, no. 3, pages 241 - 8 | - MEGENEY ET AL., GENES DEV., (1996), vol. 10, pages 1173 - 1183 | - ASAKURA ET AL., J: CELL BIOL., (2000), vol. 159, pages 123 - 134 | - ABRAMOVICI, H.; HOGAN, A.B.; OBAGI, C.; TOPHAM, M.K.; GEE, S.H., "Diacylglycerol kinasezeta localization in skeletal muscle is regulated by phosphorylation and interaction with syntrophins", MOL BIOL CELL, (2003), vol. 14, pages 4499 - 4511 | - AGUIRRE, V.; UCHIDA, T.; YENUSH, L.; DAVIS, R.; WHITE, M.F., "The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307", J BIOL CHEM., (2000), vol. 275, pages 9047 - 9054 | - BAILEY CJ; PUAH JA, "Effect of metformin on glucose metabolism in mouse soleus muscle", DIABETE METAB, (1986), vol. 12, pages 212 - 8 | - BARTON, E.R.; MORRIS, L.; MUSARO, A.; ROSENTHAL, N.; SWEENEY, H.L., "Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice", J CELL BIOL., (2002), vol. 157, pages 137 - 148 | - BARTON, E.R., "The ABCs of IGF-I isoforms: impact on muscle hypertrophy and implications for repair", APPL PHYSIOL NUTR METAB., (2006), vol. 31, pages 791 - 797 | - BLAAUW, B.; MAMMUCARI, C.; TONIOLO, L.; AGATEA, L.; ABRAHAM, R.; SANDRI, M.; REGGIANI, C.; SCHIAFFINO, S., "Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle", HUM MOL GENET., (2008), vol. 17, pages 3686 - 3696 | - CHAKKALAKAL, J.V.; HARRISON, M.A.; CARBONETTO, S.; CHIN, E.; MICHEL, R.N.; JASMIN, B.J., "Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice", HUM MOL GENET., (2004), vol. 13, pages 379 - 388 | - CHAKKALAKAL, J.V.; THOMPSON, J.; PARKS, R.J.; JASMIN, B.J., "Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies", FASEB J., (2005), vol. 19, pages 880 - 891 | - CHAKKALAKAL, J.V.; MICHEL, S.A.; CHIN, E.R.; MICHEL, R.N.; JASMIN, B.J., "Targeted inhibition of Ca2+ /calmodulin signaling exacerbates the dystrophic phenotype in mdx mouse muscle", HUM MOL GENET., (2006), vol. 15, pages 1423 - 1435 | - CHEN, Y.W.; ZHAO, P.; BORUP, R.; HOFFMAN, E.P., "Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology", J CELL BIOI., (2000), vol. 151, pages 1321 - 1336 | - CHIN, E.R.; OLSON, E.N.; RICHARDSON, J.A.; YANG, Q.; HUMPHRIES, C.; SHELTON, J.M.; WU, H.; ZHU, W.; BASSEL-DUBY, R.; WILLIAMS, R.S, "A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type", GENES DEV., (1998), vol. 12, pages 2499 - 2509 | - CHO DH. ET AL., "Myotonic dystrophy: emerging mechanisms for DM1 and DM2", BIOCHIM BIOPHYS ACTA, (2007), vol. 1772, no. 2, pages 195 - 204 | - CHUNG, J.; NGUYEN, A.K.; HENSTRIDGE, D.C.; HOLMES, A.G.; CHAN, M.H.; MESA, J.L.; LANCASTER, G.I.; SOUTHGATE, R.J.; BRUCE, C.R.; DU, "HSP72 protects against obesity-induced insulin resistance", PROC NATL ACAD SCI U S A., (2008), vol. 105, pages 1739 - 1744 | - COHEN SE; TSENG YH; MICHAEL MD; KAHN CR, "Effects of insulin-sensitising agents in mice with hepatic insulin resistance", DIABETOLOGIA, (2004), vol. 47, pages 407 - 11 | - ERVASTI, J.M.; SONNEMANN, K.J., "Biology of the striated muscle dystrophin-glycoprotein complex", INT REV CYTOL., (2008), vol. 265, pages 191 - 225 | - EVEN, P.C.; DECROUY, A.; CHINET, A., "Defective regulation of energy metabolism in mdxmouse skeletal muscles", BIOCHEM J., (1994), vol. 304, pages 649 - 654 | - FREUND AA. ET AL., ARG. NEURO ARG. NEUROPSIQIATR., (2007), vol. 65, no. 1, pages 73 - 6 | - GREGOREVIC, P.; PLANT, D.R.; LYNCH, G.S., "Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice", MUSCLE NERVE, (2004), vol. 30, pages 295 - 304 | - GUGLIERI M. ET AL., "Limb-Girdle muscular dystrophies", CURR OPIN NEUROL., (2008), vol. 21, no. 5, pages 576 - 84 | - HASEGAWA, M.; CUENDA, A.; SPILLANTINI, M.G.; THOMAS, G.M.; BUEE-SCHERRER, V.; COHEN, P.; GOEDERT, M., "Stress-activated protein kinase-3 interacts with the PDZ domain of alpha 1-syntrophin. A mechanism for specific substrate recognition", J BIOL CHEM., (1999), vol. 274, pages 12626 - 12631 | - HILDER, T.L.; TOU, J.C.; GRINDELAND, R.E.; WADE, C.E.; GRAVES, L.M., "Phosphorylation of insulin receptor substrate-1 serine 307 correlates with JNK activity in atrophic skeletal muscle", FEBS LETT., (2003), vol. 553, pages 63 - 67 | - HIROSUMI, J.; TUNCMAN, G.; CHANG, L.; GORGUN, C.Z.; UYSAL, K.T.; MAEDA, K.; KARIN, M.; HOTAMISILGIL, G.S., "A central role for JNK in obesity and insulin resistance", NATURE, (2002), vol. 420, pages 333 - 336 | - HAN, HYO-KYUNG, AAPS PHARMSCI., (2000), vol. 2, no. 1 | - HUTTUNEN KM. ET AL., J. MED. CHEM., (2009), vol. 52, no. 14, pages 4142 - 8 | - HUTTUNEN KM. ET AL., SYNTHESIS, (2008), vol. 22, pages 3619 - 3624 | - KHAIRALLAH, M.; KHAIRALLAH, R.; YOUNG, M.E.; DYCK, J.R.; PETROF, B.J.; DES ROSIERS, C., "Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy", J MOL CELL CARDIOL., (2007), vol. 43, pages 119 - 129 | - LANGENBACH, K.J.; RANDO, T.A., "Inhibition of dystroglycan binding to laminin disrupts the P13K/AKT pathway and survival signaling in muscle cells", MUSCLE NERVE, (2002), vol. 26, pages 644 - 653 | - LIQUORI CL. ET AL., "Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9", SCIENCE, (20001203), vol. 293, no. 5531, pages 864 - 7 | - LIZCANO, J.M.; ALESSI, D.R., "The insulin signalling pathway", CURR BIOL., (2002), vol. 12, pages R236 - 238 | - LUMENG, C.; PHELPS, S.; CRAWFORD, G.E.; WALDEN, P.D.; BARALD, K.; CHAMBERLAIN, J.S., "Interactions between beta 2-syntrophin and a family of microtubule-associated serine/threonine kinases", NAT NEUROSCI., (1999), vol. 2, pages 611 - 617 | - NOGRADY, Medicinal Chemistry A Biochemical Approach, OXFORD UNIVERSITY PRESS, (1985), pages 388 - 392 | - MADHAVAN, R.; JARRETT, H.W., "Calmodulin-activated phosphorylation of dystrophin", BIOCHEMISTRY, (1994), vol. 33, pages 5797 - 5804 | - MADHAVAN, R.; JARRETT, H.W., "Phosphorylation of dystrophin and alpha-syntrophin by Ca(2+)-calmodulin dependent protein kinase 11", BIOCHIM BIOPHYS ACTA, (1999), vol. 1434, pages 260 - 274 | - MISRA, P., "AMP activated protein kinase: a next generation target for total metabolic control", EXPERT OPIN THER TARGETS, (2008), vol. 12, pages 91 - 100 | - MOKHTARIAN, A.; DECROUY, A.; CHINET, A.; EVEN, P.C., "Components of energy expenditure in the mdx mouse model of Duchenne muscular dystrophy", PFLUGERS ARCH., (1996), vol. 431, pages 527 - 532 | - MUSARO, A.; MCCULLAGH, K.J.; NAYA, F.J.; OLSON, E.N.; ROSENTHAL, N., "IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1", NATURE, (1999), vol. 400, pages 581 - 585 | - MUSI N; HIRSHMAN MF; NYGREN J; SVANFELDT M; BAVENHOLM P; ROOYACKERS 0; ZHOU G; WILLIAMSON JM; LJUNQVIST 0; EFENDIC S, "Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes", DIABETES, (2002), vol. 51, pages 2074 - 2081 | - MUSI N; GOODYEAR LJ, "Insulin resistance and improvements in signal transduction", ENDOCRINE, (2006), vol. 29, pages 73 - 80 | - NAYA, F.J.; MERCER, B.; SHELTON, J.; RICHARDSON, J.A.; WILLIAMS, R.S.; OLSON, E.N., "Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo", J BIOL CHEM., (2000), vol. 275, pages 4545 - 4548 | - NOGUCHI, S., "The biological function of insulin-like growth factor-I in myogenesis and its therapeutic effect on muscular dystrophy", ACTA MYOL., (2005), vol. 24, pages 115 - 118 | - PETER, A.K.; KO, C.Y.; KIM, M.H; HSU, N.; OUCHI, N.; RHIE, S.; IZUMIYA, Y.; ZENG, L.; WALSH, K.; CROSBIE, R.H., "Myogenic Akt signaling upregulates the utrophin-glycoprotein complex and promotes sarcolemma stability in muscular dystrophy", HUM MOL GENET., (2009), vol. 18, pages 318 - 327 | - PETROF, B.J.; SHRAGER, J.B.; STEDMAN, H.H.; KELLY, A.M.; SWEENEY, H.L., "Dystrophin protects the sarcolemma from stresses developed during muscle contraction", PROC NATL ACAD SCI USA., (1993), vol. 90, pages 3710 - 3714 | - ST-PIERRE, S.J.G.; KOLODZIEJCZYK, S.M.; KNUDSON, J.C.; CHAKKALLAL, J.; JASMIN, B.; MEGENEY LA., "Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway", FASEB J., (2004), vol. 18, pages 1937 - 1939 | - SANDRI, M.; SANDRI, C.; GILBERT, A.; SKURK, C.; CALABRIA, E.; PICARD, A.; WALSH, K.; SCHIAFFINO, S.; LECKER, S.H.; GOLDBERG, A.L., "Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy", CELL., (2004), vol. 117, pages 399 - 412 | - SEMSARIAN, C.; WU, M.J.; JU, Y.K.; MARCINIEC, T.; YEOH, T.; ALLEN, D.G.; HARVEY, RP.; GRAHAM, RM., "Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signaling pathway", NATURE, (1999), vol. 400, pages 576 - 581 | - SEWRY CA., J MUSCLE RES CELL MOTIL., (2008), vol. 29, no. 6-8, pages 231 - 8 | - SCHERTZER, J.D.; LYNCH, G.S., "Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration after injury", GENE THER., (2006), vol. 13, pages 1657 - 1664 | - SCHERTZER, J.D.; RYALL, J.G.; LYNCH, G.S., "Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice", AM J PHYSIOL ENDOCRINOL METAB., (2006), vol. 291, pages E499 - E505 | - STELLA VJ ET AL., DRUGS, (1985), vol. 29, pages 455 - 473 | - STEBBINS ET AL., PNAS, (20081028), vol. 105, no. 43, pages 16809 - 16813 | - STITT, T.N.; DRUJAN, D.; CLARKE, B.A.; PANARO, F.; TIMOFEYVA, Y.; KLINE, W.O.; GONZALEZ, M.; YANCOPOULOS, G.D.; GLASS, D.J., "The IGF-1/P13K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors", MOL CELL, (2004), vol. 14, pages 395 - 403 | - STUPKA, N.; PLANT, D.R.; SCHERTZER, J.D.; EMERSON, T.M.; BASSEL-DUBY, R.; OLSON, E.N.; LYNCH, G.S., "Activated calcineurin ameliorates contraction-induced injury to skeletal muscles of mdx dystrophic mice", J PHYSIOL., (2006), vol. 575, pages 645 - 656 | - STUPKA, N.; SCHERTZER, J.D.; BASSEL-DUBY, R.; OLSON, E.N.; LYNCH, G.S., "Stimulation of calcineurin A{apha} activity attenuates muscle pathophysiology in mdx dystrophic mice", AM J PHYSIOL REGUL INTEGR COMP PHYSIOL., (2008), vol. 294, pages R983 - R992 | - SUWA M; EGASHIRA T; NAKANO H; SASAKI H; KUMAGAI S, "Metformin increases the PGC-1 alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo", J APPL PHYSIOL., (2006), vol. 101, pages 1685 - 1692 | - TAWIL R., "Facioscapulohumeral muscular dystrophy", NEUROTHERAPEUTICS, (2008), vol. 5, no. 4, pages 601 - 6 | - VAINZOF M ET AL., J MOL NEUROSCI., (2008), vol. 34, no. 3, pages 241 - 8 | - WU, H.; NAYA, F.J.; MCKINSEY, T.A.; MERCER, B.; SHELTON, J.M.; CHIN, E.R.; SIMARD, A.R.; MICHEL, R.N.; BASSEL-DUBY, R.; OLSON, E.N, "MEF2 responds to multiple calcium regulated signals in the control of skeletal muscle fiber type", EMBO J., (2000), vol. 19, pages 1963 - 1973 | - YANG, B.; JUNG, D.; MOTTO, D.; MEYER, J.; KORETZKY, G.; CAMPBELL, K.P., "SH3 domain mediated interaction of dystroglycan and Grb2", J BIOL CHEM., (1995), vol. 270, pages 11711 - 11714 | - ZHOU G; MYERS R; LI Y; CHEN Y; SHEN X; FENYK-MELODY J; WU M; VENTRE J; DOEBBER T; FUJII N, "Role of AMP-activated protein kinase in mechanism of metformin action", J CLIN INVEST., (2001), vol. 108, pages 1167 - 1174 |